Granting of partially refundable aid for the development of a new quarterly formulation of Risperidone


No votes yet
 
Related
Laboratorios Farmacéuticos ROVI, S.A. (ROVI), in compliance with the information duties set out in article 227 of the Revised Text of the...
1 min
26/08/2021
ROVI’s ESG aspects have been evaluated by Sustainalytics, a Global Leader in ESG & Corporate Governance, obtaining an “ESG Risk Rating...
1 min
09/08/2021